Advertisement
ACET vs ZTS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and ZTS is a Hold.
ACET sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ACET moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACET entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for ACET just turned positive on November 04, 2026. Looking at past instances where ACET's MACD turned positive, the stock continued to rise in 39 of 43 cases over the following month. The odds of a continued upward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.242) is normal, around the industry mean (2.904). P/E Ratio (-0.298) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ZTS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ZTS turned positive on October 06, 2026. Looking at past instances where ZTS's MACD turned positive, the stock continued to rise in 26 of 47 cases over the following month. The odds of a continued upward trend are 55%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on ZTS as a result. In 48 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
ZTS moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZTS crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +6.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in 142 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 97 of 187 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
ZTS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. ZTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.709) is normal, around the industry mean (7.659). P/E Ratio (14.551) is within average values for comparable stocks, (0.330). ZTS's Projected Growth (PEG Ratio) (6.647) is slightly higher than the industry average of (2.202). Dividend Yield (0.024) settles around the average of (0.062) among similar stocks. P/S Ratio (3.299) is also within normal values, averaging (181.047).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
ACET | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 45 Fair valued | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 18 | |
PRICE GROWTH RATING 1..100 | 95 | 45 | |
P/E GROWTH RATING 1..100 | 9 | 83 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACET's Valuation (45) in the Medical Distributors industry is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that ACET’s stock grew somewhat faster than ZTS’s over the last 12 months.
ACET's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as ZTS (100) in the Pharmaceuticals Generic industry. This means that ACET’s stock grew similarly to ZTS’s over the last 12 months.
ZTS's SMR Rating (18) in the Pharmaceuticals Generic industry is significantly better than the same rating for ACET (98) in the Medical Distributors industry. This means that ZTS’s stock grew significantly faster than ACET’s over the last 12 months.
ZTS's Price Growth Rating (45) in the Pharmaceuticals Generic industry is somewhat better than the same rating for ACET (95) in the Medical Distributors industry. This means that ZTS’s stock grew somewhat faster than ACET’s over the last 12 months.
ACET's P/E Growth Rating (9) in the Medical Distributors industry is significantly better than the same rating for ZTS (83) in the Pharmaceuticals Generic industry. This means that ACET’s stock grew significantly faster than ZTS’s over the last 12 months.
| ACET | ZTS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 61% |
| Stochastic ODDS (%) | N/A | 1 day ago 81% |
| Momentum ODDS (%) | N/A | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 55% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 49% |
| Advances ODDS (%) | N/A | 4 days ago 50% |
| Declines ODDS (%) | 1 day ago 88% | 9 days ago 63% |
| BollingerBands ODDS (%) | N/A | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 52% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACET’s FA Score shows that 1 FA rating(s) are green while ZTS’s FA Score has 1 green FA rating(s).
- ACET’s FA Score: 1 green, 4 red.
- ZTS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACET’s TA Score shows that 2 TA indicator(s) are bullish while ZTS’s TA Score has 6 bullish TA indicator(s).
- ACET’s TA Score: 2 bullish, 3 bearish.
- ZTS’s TA Score: 6 bullish, 4 bearish.
Price Growth
ACET (@Biotechnology) experienced а -18.64% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +15.43% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.74%. For the same industry, the average monthly price growth was -13.34%, and the average quarterly price growth was -20.29%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.74%. For the same industry, the average monthly price growth was +2.25%, and the average quarterly price growth was +25.89%.
Reported Earning Dates
ACET is expected to report earnings on Mar 17, 2027.
ZTS is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-7.74% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+4.74% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with PAHC. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then PAHC could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +7.48% | ||
| PAHC - ZTS | 58% Loosely correlated | +4.73% | ||
| ELAN - ZTS | 45% Loosely correlated | +3.01% | ||
| AMPH - ZTS | 35% Loosely correlated | +3.32% | ||
| SNDL - ZTS | 33% Loosely correlated | +4.44% | ||
| ACET - ZTS | 31% Poorly correlated | -2.21% | ||
More | ||||